Author:
Sirokay Judith,Uretzki Maria,Volz Thomas,Plötz Sabine G.,Hein Rüdiger,Ring Johannes
Publisher
Springer Berlin Heidelberg
Reference12 articles.
1. Davies MA, Saiag P, Robert C, et al. (2017) Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18: 863–873. http://dx.doi.org/10.1016/S1470–2045 (17)30429–1.
2. Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (Hrsg) (2018) Leitlinienprogramm Onkologie: Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.0. AWMF Registernummer: 032/024OL, http://www.leitlinienprogramm-onkologie.de/leit-linien/melanom/ (Zugegriffen: 06.05.2018)
3. Gershenwald, JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF and for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform (2017) Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67: 472–492. doi: 10.3322/caac.21409
4. Larkin J, Ascierto PA, Dréno B, et al. (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371: 1867–1876. doi: 10.1056/NEJMoa1408868
5. Long GV, Flaherty KT, Stroyakovskiy D, et al. (2017) Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 28: 1631–1639